Type 2 diabetes mellitus is a chronic metabolic disease associated with high cardiovascular
(CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of …

Heart failure (HF) affects up to over 20% of patients with type 2 diabetes (T2DM), even more
in the elderly. Although, in T2DM, both hyperglycemia and the proinflammatory status …

The high energy demands of the heart are met primarily by the mitochondrial oxidation of
fatty acids and glucose. However, in heart failure there is a decrease in cardiac …

The treatment landscape for patients with established or at high risk for cardiovascular
disease and type 2 diabetes mellitus has entirely changed over the past decade, with the …

Diabetes mellitus (DM) and cardiovascular complications are two unmet medical
emergencies that can occur together. The rising incidence of heart failure in diabetic …

Heart failure (HF) and cancer are the leading causes of death worldwide and accumulating
evidence demonstrates that HF and cancer affect one another in a bidirectional way …

Diabetes mellitus is constantly increasing worldwide. Vascular complications are the most
common in the setting of long-standing disease, claiming the greatest burden in terms of …

There is growing interest in the metabolism of ketones owing to their reported benefits in
neurological and more recently in cardiovascular and renal diseases. As an alternative to a …

Objective: To evaluate the economics and effectiveness of adding dapagliflozin or
empagliflozin to the standard treatment for heart failure (HF) for patients with reduced …

The incidence of both diabetes mellitus type 2 and heart failure is rapidly growing, and the
diseases often coexist. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new …